


## Leelamine hydrochloride

<b>Cat. No.:</b>	HY-110028
<b>CAS No.:</b>	16496-99-4
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>32</sub> ClN
<b>Molecular Weight:</b>	321.93
<b>Target:</b>	Cannabinoid Receptor; Fatty Acid Synthase (FASN); Androgen Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (77.66 mM); ultrasonic and warming and heat to 60°C				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.1063 mL	15.5313 mL	31.0627 mL
		5 mM	0.6213 mL	3.1063 mL	6.2125 mL
		10 mM	0.3106 mL	1.5531 mL	3.1063 mL
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees <sup>[1]</sup> . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis <sup>[2,3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	CB1

---

## REFERENCES

---

- [1]. Kuzu OF, et al. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. *Mol Cancer Ther.* 2014 Jul;13(7):1690-703.
- [2]. A.O. Ibegbu, et al. Therapeutic Potentials and uses of Cannabinoid Agonists in Health and Disease Conditions. *British Journal of Pharmacology and Toxicology* 3(2): 76-88, 2012
- [3]. Singh KB, et al. Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. *Mol Cancer Ther.* 2019 Aug 8.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA